List of Advanced Rx Recommended For Moderate to Severe UC Expands

The AGA has released an updated guideline on pharmacologic management of adult outpatients with UC that, for the ...

FEBRUARY 4, 2025

New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease

The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...

SEPTEMBER 5, 2024

2 Exciting New FDA Approvals For Ulcerative Colitis Treatment

In this month’s The Regueiro Report, I’d like to highlight two exciting FDA approvals for moderately to ...

JANUARY 23, 2024

Ozanimod May Benefit Patients With UC as Second-Line Therapy

The oral agent ozanimod continues to demonstrate benefit against ulcerative colitis, according to two studies ...

MAY 14, 2022

FDA Approves Zeposia for Treatment of Ulcerative Colitis

The FDA has approved ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of adults with moderately to ...

JUNE 1, 2021

Ozanimod Met Phase 3 Trial End Points for Ulcerative Colitis

Ozanimod, an oral therapy with a unique targeted mechanism of action, was effective for the control of ulcerative ...

FEBRUARY 16, 2021

First Agent in New Immunotherapy Class for UC Shows Long-Term Efficacy

Ozanimod, an oral selective sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator, provided a favorable rate of ...

JUNE 23, 2016